…
Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and other botanical-based wellness products. Its product categories include full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushrooms; and pet products under the Charlotte's Web, CBD CLINIC, and CBD MEDIC brand names. The company's products contain naturally occurring phytocannabinoids, including CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), terpenes, flavonoids, and other beneficial hemp compounds. It distributes its products through retail outlets, health care practitioners, and distributors, as well as online through its website and other third-party e-commerce sites. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Louisville, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Charlotte's Web Holdings, Inc. is a consumer wellness company that develops and sells hemp-derived CBD products such as oils, capsules and topicals through direct-to-consumer and retail channels. Long-term growth drivers include increasing consumer acceptance of CBD, potential regulatory clarity, product-line and geographic expansion, and brand recognition that may support scale and revenue recovery.
Key investment risks include ongoing regulatory uncertainty in the U.S. and abroad, intense competition and pricing pressure, operational and supply-chain risks tied to hemp cultivation and product quality, and continued profitability and cash-flow challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -29.81M | -29.81M | -23.27M | -59.22M | -137.58M |
| Net income | -29.74M | -29.85M | -23.80M | -59.31M | -137.72M |
| Selling general administrative | 41.97M | 53.25M | 75.63M | 70.06M | 97.64M |
| Gross profit | 21.70M | 21.26M | 35.57M | 19.41M | 48.59M |
| Reconciled depreciation | 6.32M | 9.98M | 15.16M | 8.97M | 11.03M |
| Ebit | - | - | - | -51.74M | -147.01M |
| Ebitda | - | - | - | -41.68M | -38.03M |
| Non operating income net other | - | - | - | 0.74M | 0.05M |
| Operating income | -20.27M | -31.99M | -40.06M | -52.49M | -147.06M |
| Interest expense | - | - | - | - | 0.00M |
| Tax provision | -0.07M | 0.04M | 0.53M | 0.09M | 0.14M |
| Non recurring | - | - | - | 1.84M | 98.00M |
| Income tax expense | - | - | - | 0.09M | 0.14M |
| Total revenue | 49.90M | 49.67M | 63.16M | 74.14M | 96.09M |
| Total operating expenses | 70.17M | 81.65M | 103.22M | 71.90M | 195.64M |
| Cost of revenue | 28.20M | 28.41M | 27.59M | 54.73M | 47.51M |
| Total other income expense net | -9.54M | 2.18M | 16.80M | -8.57M | -88.52M |
| Net income from continuing ops | -29.74M | -29.85M | -23.80M | -59.31M | -137.72M |
| Net income applicable to common shares | - | - | - | -59.31M | -137.72M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 75.27M | 113.44M | 152.55M | 187.64M | 171.51M |
| Intangible assets | 0.79M | 14.74M | 17.96M | 28.64M | 2.84M |
| Other current assets | - | 1.00M | 2.50M | 56.78M | 41.77M |
| Total liab | 77.31M | 86.36M | 96.99M | 110.14M | 41.07M |
| Total stockholder equity | -2.04M | 27.09M | 55.56M | 77.50M | 130.45M |
| Other current liab | - | - | - | 78.84M | 26.45M |
| Common stock | - | - | - | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -331.31M | -301.57M | -271.72M | -247.93M | -188.61M |
| Other liab | - | - | - | - | 0.40M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | - | - | - | 16.10M |
| Cash | 8.04M | 22.62M | 47.82M | 66.96M | 19.49M |
| Total current liabilities | 8.66M | 15.94M | 23.65M | 21.43M | 20.17M |
| Net debt | 42.81M | 21.01M | - | - | - |
| Property plant equipment | - | - | - | 29.33M | 36.09M |
| Total current assets | 30.36M | 46.98M | 78.17M | 103.76M | 95.81M |
| Long term investments | 8.80M | 10.80M | 11.00M | - | 13.00M |
| Net tangible assets | - | - | - | 77.50M | 127.60M |
| Net receivables | 0.81M | 1.26M | 1.95M | 1.85M | 19.24M |
| Long term debt | 50.85M | 43.63M | 42.53M | 37.42M | - |
| Inventory | 18.02M | 18.91M | 21.54M | 26.95M | 52.08M |
| Accounts payable | 2.19M | 3.43M | 2.86M | 10.92M | 14.62M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -247.93M | -188.61M |
| Non currrent assets other | 1.35M | 0.63M | 0.70M | 5.77M | 2.06M |
| Non current assets total | 44.91M | 79.34M | 74.38M | 35.10M | 38.93M |
| Capital lease obligations | 13.61M | 15.71M | 17.91M | 20.21M | 22.60M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -3.80M | -3.51M | 0.40M | -11.79M |
| Change to liabilities | - | - | - | 7.19M | -2.23M |
| Total cashflows from investing activities | - | - | - | 0.40M | -11.79M |
| Net borrowings | - | - | - | 52.76M | - |
| Total cash from financing activities | -0.05M | -0.14M | -0.25M | 52.39M | 8.04M |
| Change to operating activities | - | - | - | - | -6.51M |
| Net income | -29.74M | -29.85M | -23.80M | -59.31M | -137.72M |
| Change in cash | -14.58M | -25.20M | -19.14M | 47.47M | -33.31M |
| Begin period cash flow | 22.62M | 47.82M | 66.96M | 19.49M | 52.80M |
| End period cash flow | 8.04M | 22.62M | 47.82M | 66.96M | 19.49M |
| Total cash from operating activities | -14.12M | -21.26M | -15.39M | -5.32M | -29.56M |
| Issuance of capital stock | - | - | - | - | 8.26M |
| Depreciation | 6.32M | 9.98M | 15.16M | 8.97M | 11.03M |
| Other cashflows from investing activities | - | - | - | 0.66M | -6.87M |
| Change to inventory | 0.11M | -1.52M | 4.38M | 1.73M | 1.02M |
| Change to account receivables | 0.37M | 0.36M | -0.81M | 2.95M | -0.95M |
| Sale purchase of stock | - | - | - | -0.06M | 8.29M |
| Other cashflows from financing activities | - | - | - | -0.31M | -0.25M |
| Change to netincome | - | - | - | 30.63M | 115.11M |
| Capital expenditures | 0.55M | 3.85M | 3.69M | 0.27M | 4.92M |
| Change receivables | - | - | - | 2.95M | -0.95M |
| Cash flows other operating | - | - | - | 2.53M | -15.82M |
| Cash and cash equivalents changes | - | - | - | 47.47M | -33.31M |
| Change in working capital | -3.28M | -9.07M | -1.87M | 4.77M | -8.67M |
| Stock based compensation | 0.66M | 1.52M | 2.10M | 3.40M | 5.48M |
| Other non cash items | 2.29M | 6.25M | 9.09M | 3.10M | - |
| Free cash flow | -14.67M | -25.11M | -19.08M | -5.58M | -34.48M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CWBHF Charlotte's Web Holdings Inc |
0.00 0.72% |
0.18 | - | 57.80 | 1.93 | 12.67 | 3.08 | -1.98 |
| MKKGY Merck KGaA ADR |
-0.74 2.19% |
33.06 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
170.05 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.34 1.66% |
21.18 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and other botanical-based wellness products. Its product categories include full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushrooms; and pet products under the Charlotte's Web, CBD CLINIC, and CBD MEDIC brand names. The company's products contain naturally occurring phytocannabinoids, including CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), terpenes, flavonoids, and other beneficial hemp compounds. It distributes its products through retail outlets, health care practitioners, and distributors, as well as online through its website and other third-party e-commerce sites. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Louisville, Colorado.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jacques Tortoroli | CEO, Pres & Director | 1959 |
| Mr. Jared Stanley | Co-Founder & COO | 1988 |
| Mr. Greg Gould | CFO & Chief Admin. Officer | NA |
| Mr. Andres de Gortari | Chief Accounting Officer | 1976 |
| Cory Pala | Director of Investor Relations | NA |
| Mr. Stephen David Rogers | Sr. VP, Gen. Counsel & ?Corp. Sec.. | 1966 |
| Ms. Kelly Shea | Sr. VP of Gov. Affairs & Corp. Communications | NA |
| Mr. Richard L. Mohr | Advisor | 1960 |
| Mr. Tim Orr | Sr. VP of Innovation | NA |
| Mr. Perry Antelman | Exec. VP & Pres of Topicals | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.